Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/7/2025 | $45.00 | Buy | H.C. Wainwright |
| 3/31/2025 | $39.00 | Neutral | Redburn Atlantic |
| 8/2/2024 | $67.00 → $60.00 | Outperform → Market Perform | BMO Capital Markets |
| 7/24/2024 | $53.00 → $62.00 | Market Perform → Outperform | Leerink Partners |
| 7/16/2024 | $29.00 → $75.00 | Buy | Jefferies |
| 6/14/2024 | $44.00 | Underperform → Mkt Perform | Bernstein |
| 4/10/2024 | $58.00 | Peer Perform → Outperform | Wolfe Research |
| 1/2/2024 | $52.00 → $62.00 | Neutral → Buy | BofA Securities |
4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)
4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)
4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)
SC 13G/A - IONIS PHARMACEUTICALS INC (0000874015) (Subject)
SC 13G/A - IONIS PHARMACEUTICALS INC (0000874015) (Subject)
SC 13G - IONIS PHARMACEUTICALS INC (0000874015) (Subject)
Chris Schade appointed as Board ChairpersonLynne Parshall, Robert Plenge, M.D., Ph.D., and Nancy Simonian, M.D., appointed to Board of DirectorsCAMBRIDGE, Mass., July 17, 2024 /PRNewswire/ -- Alltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, today announced the appointment of Chris Schade, Growth Partner at Flagship Pioneering, as Chairperson of the Board, succeeding Noubar Afeyan, Ph.D., Co-Founder of Alltrna and Founder and CEO of Flagship Pioneering. In addition, Alltrna also announced the appointments to the company's Board of Directors of Lynne Parshall, founding Chief Opera
Contineum Therapeutics, Inc. (NASDAQ:CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced the appointment of Sarah Boyce, President and Chief Executive Officer of Avidity Biosciences, Inc. (NASDAQ:RNA), as an independent member of its Board of Directors. Ms. Boyce brings over 25 years of global commercial and clinical development expertise in the life sciences industry to Contineum's board. Ms. Boyce has extensive expertise in global pharmaceut
CARLSBAD, Calif., Dec. 14, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) today announced the appointment of Michael Yang, an experienced biopharmaceutical executive, to the Ionis Board of Directors. Mr. Yang's appointment expands the total number of Ionis Board members to 10. Mr. Yang has more than 20 years of broad senior level leadership experience in biotech, pharmaceutical and medical device companies, where he launched new platforms, expanded global revenues and diversified product lines. He most recently served as President, Chief Executive Officer and B
– Olezarsen met the primary endpoint with a statistically significant mean reduction in triglycerides versus placebo at 80 mg and 50 mg doses – – Olezarsen met all key secondary endpoints – – Olezarsen demonstrated a favorable safety and tolerability profile – – Nearly 1,500-person Phase 3 study supports the exposure database for olezarsen – – Data from pivotal Phase 3 CORE and CORE2 studies of olezarsen in severe hypertriglyceridemia (sHTG) expected in Q3 2025 – Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) today announced positive topline results from the Essence study of olezarsen in people with moderate hypertriglyceridemia (fasting triglycerides ≥150 mg/dL to <500 mg/dL) with or at risk f
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) today announced that management will conduct its 2025 virtual Annual Meeting of Stockholders followed by a general corporate update on Thursday, June 5, 2025. The agenda for the event is as follows: 5:00 p.m. – 5:15 p.m. ET (2:00 p.m. – 2:15 p.m. PT) – Virtual Annual Meeting of Stockholders All stockholders of record at the close of business on April 7, 2025, are invited to participate in the virtual Annual Meeting webcast, which will be broadcast live at www.virtualshareholdermeeting.com/IONS2025. Stockholders of record will receive an official proxy card from their brokerage firm. Each proxy card contains a 16-digit control number required
BOSTON, May 05, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, hosted a virtual investor event on its clinical programs in developmental and epileptic encephalopathies (DEEs) on Friday, May 2, 2025. "We were excited to highlight the significant opportunity in DEEs and progress Praxis is making in this field," said Marcio Souza, president and chief executive officer of Praxis. "Relutrigine continues to show tremendous promise to broadly address the DEE market
H.C. Wainwright initiated coverage of Ionis Pharma with a rating of Buy and set a new price target of $45.00
Redburn Atlantic initiated coverage of Ionis Pharma with a rating of Neutral and set a new price target of $39.00
BMO Capital Markets downgraded Ionis Pharma from Outperform to Market Perform and set a new price target of $60.00 from $67.00 previously
8-K - IONIS PHARMACEUTICALS INC (0000874015) (Filer)
10-Q - IONIS PHARMACEUTICALS INC (0000874015) (Filer)
8-K - IONIS PHARMACEUTICALS INC (0000874015) (Filer)
4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)
4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)
- Encouraging start to first independent launch with TRYNGOLZATM - - On track for second independent launch with donidalorsen PDUFA August 21, 2025 - - Increasing 2025 financial guidance by more than 20% - Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) (the "Company") today reported financial results for the first quarter ended March 31, 2025. "With an encouraging start to the TRYNGOLZA launch for familial chylomicronemia syndrome, the first of four independent launches expected over the next two years, Ionis' new chapter as a fully integrated, commercial-stage biotechnology company is well underway," said Brett P. Monia, Ph.D., chief executive officer, Ionis. "We look forward to continued m
Up to four programs in registrational phase by 2025 Planned interim analysis for ulixacaltamide Essential3 Study 1 to be conducted in Q4 2024 Topline results for Phase 2 EMBOLD study of relutrigine (PRAX-562) in SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs) expected in Q3 2024 PRAX-628 Phase 2/3 POWER1 study to initiate in Q4 2024 Initiation of additional Phase 2 study (RADIANT) for PRAX-628 in focal and generalized epilepsy in 2H 2024, with topline results expected in 1H 2025 Cash and investments of $434 million as of June 30, 2024, maintains runway into 2027 BOSTON, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a
WAINUATM U.S. launch progressing well; approved in Canada; EU approval decision expected this year Olezarsen PDUFA December 19, 2024 for FCS Positive Phase 3 donidalorsen data for HAE; preparing U.S. and EU regulatory submissions On track to achieve 2024 financial guidance CARLSBAD, Calif., Aug. 1, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) (the "Company"), today reported financial results for the second quarter of 2024. "Over the first half of this year, we continued to deliver on our goal to bring a steady cadence of medicines to people with serious dise